Corvus Pharmaceuticals : CRVS SID Investor Meeting Presentation FINAL

Published: 2026-05-14 16:02:09 ET CRVS

Published on 05/14/2026 at 04:02 pm EDT

Corvus Soquelitinib Atopic Dermatitis Phase 1 Data at the Society for Investigative Dermatology (SID) Annual Meeting

May 14, 2026

The Power to Control Immunity

Richard A. Miller, MD

President and CEO, Co-Founder

Corvus Pharmaceuticals

Albert S. Chiou, MD, MBA Clinical Professor, Dermatology and Director of Clinical Research in the Department of Dermatology Stanford University Medical Center

Kavita Sarin, MD, PhD

Professor of Dermatology

Director Stanford Skin Cancer Program

Stanford Cancer Institute Stanford University Medical Center

Today's Speakers

Time

Topic

Presenter

12:30 - 12:35 pm

Event and company introduction

Dr. Richard Miller

12:35 - 12:50 pm

Atopic dermatitis systemic therapy landscape

SID clinical data presentation

Dr. Albert Chiou

12:50 - 1:00 pm

SID immunologic and biomarker data

Dr. Kavita Sarin

1:00 - 1:10 pm

Key takeaways

Broader ITK pipeline update

Dr. Richard Miller

1:10 - 1:30 pm

Q&A

All presenters

Today's Agenda: Soquelitinib Phase 1 Clinical Data

Title: Immunologic and clinical activity of soquelitinib, a selective ITK inhibitor, in atopic dermatitis

Abstract #: 0483

Date / Time: May 14, 2026, 8:45-8:55 AM

Presenter: Kavita Sarin, MD, PhD

Oral Presentation

Title: Soquelitinib, an ITK inhibitor, Produces Prolonged Drug-Free Remissions in Atopic Dermatitis

Abstract #: LB1154

Date / Time: May 16, 2026,10:40-10:50 AM

Presenter: Albert Chiou, MD

Late-Breaking Oral Presentation

SID Presentations Highlight Immunologic and Clinical Features of Soquelitinib

Novel MOA

Oral Administration

Highly selective ITK inhibition; blocks multiple cytokines and rebalances

immune response

Oral dosing in markets dominated by injectables

Clinical Stage Pipeline in a Product

Safety/efficacy seen in placebo-controlled Phase 1 AD; enrolling Phase 2 AD with registration Phase 3 PTCL ongoing

Broad expansion potential across immune diseases (dermatology, pulmonology, GI and rheumatology)

Strong IP

Proven Management

Composition of matter protection through 2042

Experienced leadership team (rituximab and ibrutinib)

First-in-Class Immune Modulators with Broad Opportunity in Immune Disease

ITK involved in T cell differentiation

ITK blockade leads to reduction in Th2, Th17

and cytokines

TH1

T-bet

Th1 cells play a role in cancer

cell and viral elimination

TH1

T-bet

Th1 cells play a role in cancer

cell and viral elimination

APC

Naïve

CD4+

T cell

ITK

TH2

GATA3

IL-4

IL-5 IL-9 IL-13

IL-31 Th2 and Th17 cells are

involved in autoimmune, inflammatory, fibrotic

Naïve

CD4+

T cell

ITK

TH2

GATA3

IL-4

IL-5 IL-9 IL-13

IL-31 Th2 and Th17 cells are

involved in autoimmune, inflammatory, fibrotic

Th17

RORγΤ

IL-17

IL-21 IL-22 IL-23

GM-CSF TNFa

and allergic diseases

Th17

RORγΤ

IL-17

IL-21 IL-22 IL-23

GM-CSF TNFa

and allergic diseases

Soquelitinib Blocks Th2 and Th17

Modulation of T cell differentiation

Th17

RORγΤ

and allergic diseases

IL-17

IL-21 IL-22 IL-23

GM-CSF TNFa

IL-4

IL-5 IL-9 IL-13

IL-31 Th2 and Th17 cells are

involved in autoimmune, inflammatory, fibrotic

TH2

GATA3

ITK

Naïve

CD4+

T cell

APC

Th1 cells play a role in cancer

cell and viral elimination

TH1

T-bet

ITK involved in T cell differentiation

Treg

Blocking ITK results in

increase in Tregs and decrease in Th17

IL-17

IL-21 IL-22 IL-23

GM-CSF TNFa

Th17

RORγΤ

IL-4

IL-5 IL-9 IL-13 IL-31

TH2

GATA3

ITK

Naïve

CD4+

T cell

APC

TH1

T-bet

Sci Signal 17:1, 2024 (DOI: 10.1126/scisignal.adh2381)

PLOS ONE 14 (4): 1, 2019 (https://doi.org/10.1371/journal.pone.0215963)

Foxp3

ITK blockade leads to switch to Treg

ITK Regulates Switch from Th17 to Tregs

Rebalancing immunity leads to durable responses

Th2

Th17

ILC2

Treg

IL-4

IL-5

IL-13

IL-31

IL-17

IL-21

IL-22

SOQUELITINIB

DUPIXENT®

EBGLYSS

NEMLUVIO®

RINVOQ®

SOQUELITINIB

Inhibits cells responsible for Restores immune balance production and control of by enhancing T regs

many inflammatory cytokines

Soquelitinib Effects Multiple Inflammatory Pathways

Comparison to other agents

SID clinical data presentation

Atopic Dermatitis Therapy Landscape

…carry a black box warning

…require regular blood

monitoring

Oral therapies (JAK inhibitors) are effective, but…

…novel MOA to address relapsed/refractory

patients

…safe oral therapy

…shorter and simpler treatment regiments

…no requirement for lab monitoring

…lasting remissions

There is a need for new treatment

options that can provide…

…responses can vary across

individuals

…require injections

…can have side effects

Biologic therapies are effective, but…

Albert S. Chiou, MD

Clinical Professor, Dermatology and Director of Clinical Research in the Department of Dermatology

Stanford University Medical Center

Albert Chiou1, Michael Cameron2, Jennifer L. Parish3, Jorge Garcia-Zuazaga4, Stephen Schleicher5, Lih-Yun Hsu6, Drew Hotson6, Sinem Bagci6, Suresh Mahabhashyam6, Richard Miller6

1Stanford University, Palo Alto, CA, United States; 2Equity Medical LLC, New York, NY, United States;

3Paddington Testing Co Inc, Philadelphia, PA, United States; 4Apex Clinical Research Center, Mayfield Heights, OH, United States; 5Best Skin Research LLC, Camp Hill, PA, United States; 6Corvus Pharmaceuticals Inc, So. San Francisco, CA, United States

Placebo N = 4

Randomized

3:1

4 weeks treatment

At least 1 prior topical or systemic therapy

Participants with moderate to severe AD

N = 72

Cohort 4

N = 24

Randomized

3:1

4 weeks treatment

Placebo N = 4

Soquelitinib 100 mg BID N = 12

Cohort 1

N =16

Randomized

3:1

4 weeks treatment

Placebo

N = 4

Soquelitinib 200 mg QD N = 12

Cohort 2

N = 16

Soquelitinib 200 mg BID N = 12

Cohort 3

N = 16

Endpoints:

Primary: safety

Secondary: % change in EASI, EASI75, EASI90, IGA 0 or 1

Design

Blinded with placebo

No concomitant topical steroids

28 day treatment for cohorts 1-3 (3:1

randomization)

56 day treatment for cohort 4 (1:1 randomization)

Off treatment follow up

Prior systemic therapy allowed

14 sites all U.S.

Study Design

Soquelitinib 200 mg BID N = 12

Randomized

1:1

Placebo

N = 12

8 weeks

treatment

4-week

8-week

Cohorts 1 and 2

Cohort 3

Cohorts 1-3

Cohort 4

Soquelitinib

100 mg BID or 200 mg QD (n=24)

Soquelitinib 200 mg BID (n=12)

Placebo (n=12)

Soquelitinib 200 mg BID (n=12)

Placebo (n=12)

Age, mean (range), yrs

44.4

(21-66)

46.4

(25-71)

38.8

(20-62)

40.5

(18-69)

42.3

(21-67)

Gender, male n (%)

14 (58.3)

4 (33.3)

7 (58.3)

6 (50)

7 (58.3)

Race/ethnicity, n (%) Asian

Black or African American White

Hispanic or Latino Not Reported

2 (8.3)

13 (54.2)

4 (16.7)

5 (20.8)

0 (0)

5 (41.7)

4 (33.3)

2 (16.7)

1 (8.3)

5 (41.7)

2 (16.7)

4 (33.3)

0 (0)

3 (25)

5 (41.7)

3 (25)

1 (8.3)

0 (0)

2 (16.7)

5 (41.7)

2 (16.7)

3 (25)

0 (0)

Baseline EASI, mean (range)

19.9 (14.7-46.6)

27.2 (18.0-41.5)

21.2 (14.4-46.6)

25.7 (16.6-64.7)

21.9 (16.4-32.9)

Baseline IGA 4, n (%) 2 (8.3)

1 (8.3)

2 (16.7)

1 (8.3)

Prior AD therapies, n (%) Topical corticosteroids

24 (100)

12 (100)

Systemic therapies

6 (25)

4 (33.3)

3 (25)

5 (41.7)

7 (58.3)

Dupilumab JAK inhibitor Other

2 (8.3)

0 (0)

4 (16.7)

2 (16.7)

1 (8.3)

4 (33.3)

2 (16.7)

0 (0)

2 (16.7)

1 (8.3)

5 (41.7)

3 (25)

2 (16.7)

6 (50)

Cohorts 1-3

Soquelitinib

Placebo

Cohorts 1 and 2

(N=24)

Cohort 3

(N=12)

Combined

(N=12)

EASI 75 (%pts)

IGA 0 or 1 (%pts)

EASI 50 (%pts)

EASI 90 (%pts)

Change EASI Mean % Reduction

54.6

64.8

34.4

Cohorts 1, 2, and 3

Treg increase in blood

200

PBO Combined

150 SQL Cohort 1

SQL Cohort 2

100 SQL Cohort 3

-50

D1 D28 D58

Change from baseline at Day 28 and at Day 58 (n=9 Cohort 1, n=12 Cohort 2, n=12 Cohort 3 green)

Treg: CD45+, CD4+, CD25high, Foxp3+

% change over baseline

Durable remission with increase in Tregs in Cohort 3

On Treatment

Off Treatment

Worsening within 4 weeks of stopping therapy

Rebound

Abrocitinib (JAK1 inhibitor)1

Rebound

Upadacitinib (JAK1 inhibitor)2

Rebound

STAT6 inhibitor4

Rebound

Dupilumab (IL-4 / IL-13)3

LS mean percent improvement (± SE) in EASI score from SOLO baseline during

SOLO-CONTINUE (MI)

1 - JAMA Derm 155:1371, 2019; 2 - J Eur Acad Dermatol Venereol. 2023;37:2558-2568; 3 - JAMA Dermatol. 2020;156(2):131-143; 4 - AAD 2026 presentation 18

Cohort 4 achieved 75% EASI 75

Cohort 4 (200 mg BID)

Soquelitinib (N=12)

8-week

Placebo (N=12)

EASI 75 (%pts)

20*

IGA 0 or 1 (%pts)

EASI 50 (%pts)

30*

EASI 90 (%pts)

Change EASI Mean % Reduction

40*

Flare (requiring rescue meds) (%pts)

*2 placebo patients missed the Day 56 visit and are not included. They did return for later visits and did not achieve EASI 75 at any time point. If included in the placebo analysis the 8-week EASI 75 is 17%.

Increased efficacy with longer duration of treatment (8 weeks)

Disclaimer

Corvus Pharmaceuticals Inc. published this content on May 14, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 14, 2026 at 20:01 UTC.